These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22788747)

  • 1. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
    Huang CY; Shih CM; Tsao NW; Lin YW; Huang PH; Wu SC; Lee AW; Kao YT; Chang NC; Nakagami H; Morishita R; Ou KL; Hou WC; Lin CY; Shyu KG; Lin FY
    Br J Pharmacol; 2012 Dec; 167(7):1506-19. PubMed ID: 22788747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression.
    Shih CM; Chen YH; Lin YW; Tsao NW; Wu SC; Kao YT; Chiang KH; Li CY; Chang NC; Lin CY; Huang CY; Lin FY
    Curr Med Chem; 2014 Jun; 21(17):2012-22. PubMed ID: 24059225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin modulates ischemia-induced endothelial progenitor cell mobilization and neovascularization in diabetic mice.
    Dong L; Kang L; Ding L; Chen Q; Bai J; Gu R; Li L; Xu B
    Microvasc Res; 2011 Nov; 82(3):227-36. PubMed ID: 21964072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin therapy enhances the number of circulating angiogenic cells and angiogenesis-evaluations in vitro and in the rat critical limb ischemia model.
    Chua S; Sheu JJ; Chen YL; Chang LT; Sun CK; Leu S; Sung HC; Tsai TH; Chung SY; Yeh KH; Cho CL; Kao YH; Yip HK
    Cytotherapy; 2013 Sep; 15(9):1148-63. PubMed ID: 23849976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
    Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
    PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes.
    Dai X; Zeng J; Yan X; Lin Q; Wang K; Chen J; Shen F; Gu X; Wang Y; Chen J; Pan K; Cai L; Wintergerst KA; Tan Y
    J Cell Mol Med; 2018 Jan; 22(1):89-100. PubMed ID: 28799229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
    Fadini GP; Boscaro E; Albiero M; Menegazzo L; Frison V; de Kreutzenberg S; Agostini C; Tiengo A; Avogaro A
    Diabetes Care; 2010 Jul; 33(7):1607-9. PubMed ID: 20357375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.
    Lin FY; Shih CM; Huang CY; Tsai YT; Loh SH; Li CY; Lin CY; Lin YW; Tsai CS
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1111-1127. PubMed ID: 32623597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization.
    Hiasa K; Ishibashi M; Ohtani K; Inoue S; Zhao Q; Kitamoto S; Sata M; Ichiki T; Takeshita A; Egashira K
    Circulation; 2004 May; 109(20):2454-61. PubMed ID: 15148275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study.
    Price JD; Linder G; Li WP; Zimmermann B; Rother KI; Malek R; Alattar M; Tarbell KV
    Clin Exp Immunol; 2013 Oct; 174(1):120-8. PubMed ID: 23711188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.
    Joo KW; Kim S; Ahn SY; Chin HJ; Chae DW; Lee J; Han JS; Na KY
    BMC Nephrol; 2013 Apr; 14():98. PubMed ID: 23621921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
    Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.
    Abd El Motteleb DM; Elshazly SM
    Eur J Pharmacol; 2013 Nov; 720(1-3):158-65. PubMed ID: 24238127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
    J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of DPP-IV inhibition in NOD mice with overt diabetes.
    Vargová L; Zacharovová K; Dovolilová E; Vojtová L; Cimburek Z; Saudek F
    Folia Biol (Praha); 2013; 59(3):116-22. PubMed ID: 23890479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions.
    Huang PH; Chen JW; Lin CP; Chen YH; Wang CH; Leu HB; Lin SJ
    Cardiovasc Diabetol; 2012 Aug; 11():99. PubMed ID: 22894755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.